Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026
Rapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48Four presentations build on the previously reported Phase 3 RINGSIDE resultsImmunome, Inc.
Immunome shared new test results showing their medicine helps desmoid tumor patients feel better. When a company shows good patient results, investors watch to see if the medicine will get approved.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.